Nothofagin has antioxidant, and antithrombotic activities, it possesses anti-inflammatory activity by inhibiting hyperpermeability, expression of CAMs, and adhesion and migration of leukocytes, thereby endorsing its usefulness as a therapy for vascular inflammatory diseases.

Pre-treatment of DNPHSA-stimulated RBL-2H3 with 10 μM Nothofagin markedly suppresses the phosphorylation of Lyn, Syk, and Akt. Nothofagin pre-treatment (0.1, 1, 10 μM) decreases the level of histamine release in RBL-2H3 and RPMCs cells. Furthermore, Nothofagin suppresses IgE-mediated mast cell degranulation both in vitro and in vivo [1].

Oral administration of matrine at 1 mg/kg per day for 7 consecutive days significantly increases the urinary volume of both normotensive (NTR) and spontaneously hypertensive rats (SHR) [2].